RESUMEN
BACKGROUND: Due to the high incidence and demographic development, there is an urgent need for healthcare research data on lower urinary tract symptoms due to benign prostatic hyperplasia (LTUS/BPH). Since 2005 the Governing Body of German Prostate Centers (DVPZ) has been collecting data from 22 prostate centers in order to determine the quality and type of cross-sectoral care in particular for LUTS/BPH patients. OBJECTIVES: Presentation of the DVPZ database in general, as well as an investigation of treatment patterns for medical and instrumental therapies. MATERIALS AND METHODS: The analysis is based on UroCloud data sets from 30 November 2017. In the UroCloud data on diagnostics, therapy and course of disease are recorded in a web-based manner. RESULTS: A total of 29,555 therapies were documented for 18,299 patients (1.6/patient), divided into 48.5% instrumental, 29.2% medical treatment, and 18.0% "wait and see" (in 4.3% no assignment was possible). Patients treated with an instrumental therapy were oldest (median: 72 years, interquartile range: 66-77), had the largest prostate volumes (50â¯ml, 35-75â¯ml), and were mostly bothered by symptoms (International Prostate Symptom Scoreâ¯= 19/4). The majority of patients under medical treatment received alphablockers (56%); phytotherapeutics were used least frequently (3%). Instrumental therapies are dominated by transurethral resection (TUR) of the prostate (60.0%), open prostatectomy (9.4%) and laser therapy (5.0%), with laser therapy having the shortest hospital stay (5 days) and the lowest transfusion and re-intervention rates (1.0% and 4.6%, respectively). CONCLUSIONS: The DVPZ certificate covers the complete spectrum of cross-sectoral care for LUTS/BPH patients and documents the use of the various therapies as well as their application and effectiveness in the daily routine setting.
Asunto(s)
Antagonistas Adrenérgicos alfa/uso terapéutico , Terapia por Láser , Síntomas del Sistema Urinario Inferior/terapia , Hiperplasia Prostática/complicaciones , Resección Transuretral de la Próstata , Anciano , Terapia Combinada , Alemania , Humanos , Incidencia , Síntomas del Sistema Urinario Inferior/etiología , Masculino , Prostatectomía , Hiperplasia Prostática/terapia , Resultado del TratamientoRESUMEN
PURPOSE: Dermatologic events (DEs) in patients with cancer treated with lapatinib, a small-molecule dual tyrosine kinase inhibitor (TKI) of epidermal growth factor receptor (EGFR [ErbB1]) and HER2 (ErbB2), were characterized. PATIENTS AND METHODS: Nine clinical trials of metastatic cancer were included in this analysis. Lapatinib was administered at doses ranging from 1000 to 1500 mg/day as monotherapy (n=928) or in combination with paclitaxel or capecitabine (n=491). Patients not treated with lapatinib comprised the control group. Dermatologic events included hand-foot syndrome, rash, hair disorder, dry skin, pruritus/urticaria, skin disorder, skin infection, and nail disorder; DEs were characterized based on type, time to onset, severity, duration, and required interventions. RESULTS: Fifty-eight percent of patients treated with lapatinib monotherapy, 74% treated with lapatinib plus paclitaxel or capecitabine, and 53% in the control group developed DEs. Among patients receiving lapatinib monotherapy, 55% experienced grade 1/2 DEs, 3% had grade 3 DEs, and no grade 4 DEs were observed. The most common DE was rash (43%); all other events occurred in Asunto(s)
Neoplasias/tratamiento farmacológico
, Quinazolinas/administración & dosificación
, Quinazolinas/efectos adversos
, Enfermedades de la Piel/etiología
, Adulto
, Anciano
, Anciano de 80 o más Años
, Protocolos de Quimioterapia Combinada Antineoplásica/administración & dosificación
, Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos
, Capecitabina
, Ensayos Clínicos como Asunto
, Desoxicitidina/administración & dosificación
, Desoxicitidina/análogos & derivados
, Relación Dosis-Respuesta a Droga
, Receptores ErbB/metabolismo
, Exantema/etiología
, Femenino
, Fluorouracilo/administración & dosificación
, Fluorouracilo/análogos & derivados
, Humanos
, Lapatinib
, Masculino
, Persona de Mediana Edad
, Neoplasias/complicaciones
, Paclitaxel/administración & dosificación
, Resultado del Tratamiento
RESUMEN
Following surgical excision of a prevesical haematoma, topical negative pressure was used to promote wound closure. The development of a vesicocutaneous fistula at the incision site may have been an indirect complication of the therapy.
Asunto(s)
Hematoma/cirugía , Dehiscencia de la Herida Operatoria/terapia , Fístula de la Vejiga Urinaria/terapia , Anciano , Femenino , Humanos , Espacio Retroperitoneal , Succión/efectos adversos , Dehiscencia de la Herida Operatoria/complicaciones , Enfermedades de la Vejiga Urinaria/etiología , Enfermedades de la Vejiga Urinaria/cirugía , Fístula de la Vejiga Urinaria/etiologíaRESUMEN
BACKGROUND: In prostate centers of the Governing Body of German Prostate Centers (DVPZ, Dachverband der Prostatazentren Deutschlands e.V.) treatment data from 3 university clinics, 21 treatment clinics, 3 private clinics and 330 general practitioners incorporated under 22 certificates are collated, in order to document the quality and type of cross-sectoral and interdisciplinary treatment, in particular of prostate cancer (PCA) patients. METHODS: This analysis is based on the DVPZ UroCloud data sets from 20 July 2015. The UroCloud reflects the web-based chronological disease development and quality parameters. For the descriptive analysis of particular key figures, available complete data sets were selected. RESULTS: Of the centers 22 held a valid certificate and fulfilled all required case numbers and structural prerequisites at the primary certification or recertification. In three cases a reauditing led to requirements before certification. Since 2005 a total of 9650 PCA patients have been pseudonymized and followed up (41,247 follow-up forms, 4.3 forms per patient). In 2014 the median number of newly documented PCA patients was 61 per center (minimum 7 and maximum 295). Radical prostatectomy (RP) dominated with 4491 (56 %) cases followed by primary hormonal therapy (1210 cases, 15 %), irradiation (809, 10 %) and non-interventional therapy, such as active surveillance (AS) or watchful waiting (WW) in 760 cases (10 %). A prostate-specific antigen (PSA) reduction was documented in 50 % of the patients with a preoperative PSA value > 20, in 60 % of pT4 tumors and in 50 % of patients with a tumor Gleason score of 9-10. A positive incision margin (R+) was found in in 15 % of pT2 stages, 41 % of pT3 stages and 85 % of pT4 stages. A secondary intervention was documented in 6.5 % of RP. CONCLUSION: The DVPZ certificate reflects the complete spectrum of treatment of PCA patients. The strength of the certificate lies in the documentation of patient development and a simultaneous collation of quality parameters.
Asunto(s)
Servicio de Oncología en Hospital/estadística & datos numéricos , Servicio de Oncología en Hospital/normas , Neoplasias de la Próstata/epidemiología , Neoplasias de la Próstata/terapia , Garantía de la Calidad de Atención de Salud/estadística & datos numéricos , Sistema de Registros , Adulto , Anciano , Anciano de 80 o más Años , Alemania/epidemiología , Adhesión a Directriz/estadística & datos numéricos , Humanos , Masculino , Oncología Médica/normas , Persona de Mediana Edad , Guías de Práctica Clínica como Asunto , Garantía de la Calidad de Atención de Salud/normas , Resultado del TratamientoRESUMEN
BACKGROUND: Ischemia-reperfusion injury (IRI) can result in severe organ dys- or nonfunction. Interaction of leukocytes and endothelial cells mediated by E-selectin appears to be a key step for disturbed microcirculation. Therefore we studied gene and protein expression as well as localization of E-selectin during intestinal IRI. METHODS: Intestinal tissue samples were obtained from extracorporeal perfused intestines (cold ischemia time [CIT] 2 or 20 hours, each n = 5) and additionally in intestinal transplanted pigs (CIT 2 or 20 hours, each n = 1). Mucosal damage was graded according to the Chiu classification. E-selectin mRNA was determined by PCR and quantitative RT-PCR. Localization of E-selectin mRNA was performed by in situ hybridization and of the protein by immunohistochemistry. RESULTS: Histologically, mucosal damage occurred during reperfusion and was earlier and more severe after 20 hours of CIT. E-selectin mRNA expression was detected by PCR already after laparotomy and was elevated after reperfusion. Interestingly, mRNA expression was already increased after 20 hours of CIT. E-selectin mRNA was localized to the luminal surface of muscular, submucosal, and mucosal endothelial cells and the protein was detected on submucosal arterial endothelium as early as 2 hours after reperfusion. CONCLUSION: Prolongation of CIT results in more severe mucosal damage during reperfusion, which is associated with protein expression of E-selection that might be used as a marker for activated endothelial cells. Increased E-selectin mRNA at end of 20 hours of CIT might indicate a preactivated state of endothelial cells potentially triggered by bacterial translocation or products.
Asunto(s)
Selectina E/genética , Intestinos/irrigación sanguínea , Intestinos/fisiología , Daño por Reperfusión/genética , Animales , Mucosa Intestinal/irrigación sanguínea , Mucosa Intestinal/patología , Intestinos/trasplante , Isquemia , ARN Mensajero/genética , Porcinos , Transcripción Genética/genéticaAsunto(s)
Simulación por Computador , Electrocoagulación/instrumentación , Neoplasias Renales/cirugía , Planificación de Atención al Paciente , Animales , Humanos , Riñón/patología , Riñón/cirugía , Neoplasias Renales/patología , Imagen por Resonancia Magnética/instrumentación , Sistemas en Línea/instrumentación , Programas Informáticos , Porcinos , Tomografía Computarizada por Rayos X/instrumentaciónAsunto(s)
Hepatopatías/patología , Trasplante de Hígado/patología , Donadores Vivos , Complicaciones Posoperatorias/patología , Rotura Espontánea/patología , Adulto , Femenino , Hepatectomía/métodos , Humanos , Complicaciones Intraoperatorias/patología , Imagen por Resonancia Magnética , Persona de Mediana Edad , Derrame Pleural/patología , Vena Porta/patología , Trombosis/patología , Recolección de Tejidos y Órganos/métodos , Resultado del TratamientoAsunto(s)
Hemodinámica , Mucosa Intestinal , Intestino Delgado , Animales , Presión Sanguínea , Técnicas In Vitro , Mucosa Intestinal/irrigación sanguínea , Mucosa Intestinal/fisiología , Intestino Delgado/irrigación sanguínea , Intestino Delgado/fisiología , Isquemia , Arteria Mesentérica Superior/fisiología , Modelos Biológicos , Perfusión/instrumentación , Perfusión/métodos , Vena Porta/fisiología , Daño por Reperfusión , PorcinosAsunto(s)
Inmunosupresores/farmacocinética , Intestinos/fisiología , Ácido Micofenólico/farmacocinética , Tacrolimus/farmacocinética , Animales , Biotransformación , Sangre , Técnicas In Vitro , Modelos Biológicos , Ácido Micofenólico/análogos & derivados , Perfusión , Porcinos , Trasplante HomólogoRESUMEN
PURPOSE: Gastrin releasing peptide (GRP) is a growth factor for renal cell carcinoma (RCC) and it has vasoactive properties. Blockade of GRP receptor inhibits the growth of GRP receptor positive and negative tumors in nude mice, suggesting GRP effects other than those related to tumor epithelium. Therefore, in this study we analyzed the effects of GRP receptor blockade on neoangiogenesis in RCC. MATERIALS AND METHODS: GRP receptor expression was determined in human RCC and corresponding normal tissue by real-time reverse transcriptase-polymerase chain reaction, immunohistochemistry and confocal laser scanning microscopy. Multicellular spheroids of the A498 RCC line were implanted into dorsal skin fold chambers of athymic nude mice. Neoangiogenesis was measured by intravital microscopy after blockade of GRP receptors by the GRP antagonist RC-3095. The influence of GRP on vascular endothelial growth factor secretion in A498 cells was studied in vitro. RESULTS: GRP receptor expression was immunolocalized in tumor cells and microvessels. Implanted tumor cell spheroids and spheroid microvessels of the chamber also expressed GRP receptors. Spheroid neoangiogenesis was significantly inhibited by RC-3095 when given immediately after spheroid implantation. Vascular endothelial growth factor secretion of A498 cells was not affected by GRP. CONCLUSIONS: RCC angiogenesis is sensitive to GRP receptor blockade. Therefore, GRP receptors may not only stimulate tumor cell proliferation, but also affect tumor microcirculation.
Asunto(s)
Carcinoma de Células Renales/irrigación sanguínea , Neoplasias Renales/irrigación sanguínea , Neovascularización Patológica/genética , Receptores de Bombesina/genética , Animales , Carcinoma de Células Renales/patología , División Celular/genética , Línea Celular Tumoral , Endotelio Vascular/patología , Regulación Neoplásica de la Expresión Génica/fisiología , Humanos , Neoplasias Renales/patología , Masculino , Ratones , Ratones Desnudos , Microcirculación/patología , Microscopía Confocal , Estadificación de Neoplasias , Trasplante de Neoplasias , Reacción en Cadena de la PolimerasaRESUMEN
Phospholipases are important pathogenicity determinants in Candida albicans. They play a significant role in damaging cell membranes and invading host cells. High phospholipase production is correlated with an increased ability of adherence and a higher mortality rate in animal models. By means of an egg yolk-containing agar and the Pz (= phospholipase activity zone) value according to Price, the present study investigated phospholipase production in 170 strains of C. albicans. At an incubation temperature of 37 degrees C, Pz values ranged from 0.395 to 1; no clear relationship was found between clinical origin of the isolates and severity of the disease. In addition to C. albicans, a total of 110 strains of 16 other yeast species were investigated for possible phospholipase production. Only yeasts of the species Rhodotorula rubra showed phospholipase activity, with mean values exceeding those observed in C. albicans. This result was confirmed by an assay using sterile culture filtrates and phosphatidyl-[3H-methyl]-choline-dipalmitoyl as a substrate. Since Rh. rubra has only rarely been demonstrated as a pathogen in humans, we believe that factors such as reduced growth at 37 degrees C, absence of dimorphism and low ability of adherence lessen the importance of high phospholipase activity in Rh. rubra as a pathogenicity determinant. Therefore, potential virulence factors should always be considered in the context of the whole spectrum of pathogenic determinants.